Sara Lonardi

Head of Dept

Istituto Oncologico Veneto

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Sara Lonardi is the Head of the Department at Istituto Oncologico Veneto in Italy. Her research areas focus on cancer treatment strategies, particularly in the context of immunotherapy and targeted therapies for various gastrointestinal cancers. Recent publications include investigations into the pharmacological profiles of monoclonal antibodies, the efficacy of immune checkpoint inhibitors, and quality-of-life analyses in cancer treatment protocols.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (2)

david tougeron

FRANCE

View details

Gaya Spolverato

University of Padua

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sara Lonardi

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis

Quality of Life in Rectal Cancer Treatments: An Updated Systematic Review of Randomized Controlled Trials (2013–2023)

Clinical Pharmacology Profile of the Claudin 18.2 Antibody Zolbetuximab

MSI-H locally recurrent rectal cancer: Immune checkpoint inhibitors vs. standard chemotherapy and pelvic exenteration

Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial

Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial

The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial

First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer

Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, Italy, and Germany

Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials

Collaborators (2)

david tougeron

Gaya Spolverato

Make your next move.